Celiac disease: a model autoimmune disease with gene therapy applications.
Gene therapy (GT) is still at the 'experimental' stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality.
Institute of Child Health, University College London, London, UK. m.londei@ich.uce.ac.uk
M
M
Londei
S
S
Quaratino
L
L
Maiuri
D000818:Animals; D015551:Autoimmunity; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002446:Celiac Disease / Q000276:immunology*; D015316:Genetic Therapy / Q000379:methods*; D005903:Gliadin / Q000276:immunology; D005983:Glutens / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007378:Interleukins / Q000276:immunology; D007413:Intestinal Mucosa / Q000276:immunology; D007421:Intestine, Small / Q000276:immunology; D008213:Lymphocyte Activation; D018448:Models, Immunological
D007378:Interleukins; D005983:Glutens; D005903:Gliadin